Barclays analyst Peter Lawson maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $0.99.
According to TipRanks, Lawson is a 3-star analyst with an average return of 1.3% and a 42.13% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Syndax Pharmaceuticals, and Arcus Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karyopharm Therapeutics with a $4.33 average price target, a 337.46% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.
KPTI market cap is currently $104.8M and has a P/E ratio of -0.71.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Karyopharm Therapeutics (KPTI) Company Description:
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
